JP2004529884A - 金属放射性医薬のためのアスコルビン酸類似体 - Google Patents

金属放射性医薬のためのアスコルビン酸類似体 Download PDF

Info

Publication number
JP2004529884A
JP2004529884A JP2002567231A JP2002567231A JP2004529884A JP 2004529884 A JP2004529884 A JP 2004529884A JP 2002567231 A JP2002567231 A JP 2002567231A JP 2002567231 A JP2002567231 A JP 2002567231A JP 2004529884 A JP2004529884 A JP 2004529884A
Authority
JP
Japan
Prior art keywords
radiopharmaceutical
substituted
formula
metal
biomolecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002567231A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004529884A5 (https=
Inventor
シュアン・リュー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Pharma Co
Original Assignee
Bristol Myers Squibb Pharma Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Pharma Co filed Critical Bristol Myers Squibb Pharma Co
Publication of JP2004529884A publication Critical patent/JP2004529884A/ja
Publication of JP2004529884A5 publication Critical patent/JP2004529884A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/121—Solutions, i.e. homogeneous liquid formulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP2002567231A 2001-02-26 2002-02-22 金属放射性医薬のためのアスコルビン酸類似体 Pending JP2004529884A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27138901P 2001-02-26 2001-02-26
PCT/US2002/005155 WO2002067859A2 (en) 2001-02-26 2002-02-22 Ascorbic acid analogs for metalloradiopharmaceuticals

Publications (2)

Publication Number Publication Date
JP2004529884A true JP2004529884A (ja) 2004-09-30
JP2004529884A5 JP2004529884A5 (https=) 2005-12-22

Family

ID=23035343

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002567231A Pending JP2004529884A (ja) 2001-02-26 2002-02-22 金属放射性医薬のためのアスコルビン酸類似体

Country Status (12)

Country Link
US (1) US6713042B2 (https=)
EP (1) EP1365813A4 (https=)
JP (1) JP2004529884A (https=)
CN (1) CN1503680A (https=)
AU (1) AU2002253999A1 (https=)
BR (1) BR0207315A (https=)
CA (1) CA2438204A1 (https=)
CZ (1) CZ20032597A3 (https=)
HU (1) HUP0304083A2 (https=)
IL (1) IL157359A0 (https=)
MX (1) MXPA03007595A (https=)
WO (1) WO2002067859A2 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008056481A1 (en) * 2006-11-09 2008-05-15 Nihon Medi-Physics Co., Ltd. Radioactive diagnostic imaging agent
JP2012502060A (ja) * 2008-09-05 2012-01-26 モレキュラ インサイト ファーマシューティカルズ インコーポレイテッド 放射性ヨウ素化ベンズアミド誘導体の薬学的組成物およびそれを作製する方法
JP2012524064A (ja) * 2009-04-15 2012-10-11 ランセウス メディカル イメージング， インコーポレイテッド アスコルビン酸による放射性医薬組成物の安定化
JP2016510342A (ja) * 2013-02-15 2016-04-07 トーマス・ジェファーソン・ユニバーシティＴｈｏｍａｓ Ｊｅｆｆｅｒｓｏｎ Ｕｎｉｖｅｒｓｉｔｙ 腫瘍画像化のためのキット

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10305463A1 (de) * 2003-02-04 2004-08-12 Schering Ag Enantiomerenreines (4S,8S)- und (4R,8R)-4-p-Nitrobenzyl-8-methyl-3,6,9-triza-3N,6N,9N-tricarboxymethyl-1,11-undecandisäure und deren Abkömmlinge, Verfahren zu deren Herstellung und Verwendung zur Herstellung pharmazeutischer Mittel
US20050089471A1 (en) * 2003-10-24 2005-04-28 Johnson Bruce F. Labeled ligands for lectin-like oxidized low-density lipoprotein receptor (LOX-1)
US20050089470A1 (en) * 2003-10-24 2005-04-28 Johnson Bruce F. Labeled peptides for lectin-like oxidized low-density lipoprotein receptor (LOX-1)
US20060210479A1 (en) * 2004-08-10 2006-09-21 Dow Global Technologies Inc. Targeting chelants and chelates
GB0427392D0 (en) * 2004-12-15 2005-01-19 Amersham Plc Stabilised 99mTc compositions
TW200803903A (en) * 2006-04-28 2008-01-16 Nihon Mediphysics Co Ltd Novel compound having affinity to amyloid
RU2008150377A (ru) * 2006-05-19 2010-06-27 Нихон Меди-Физикс Ко., Лтд. (Jp) Новое соединение, обладающее сродством к амилоиду
CN101501033B (zh) * 2006-06-21 2012-08-01 通用电气医疗有限公司 对淀粉状蛋白具有亲和性的化合物
PL2029178T3 (pl) * 2006-06-21 2012-08-31 Ge Healthcare Ltd Produkty radiofarmaceutyczne
KR20090091287A (ko) * 2006-11-17 2009-08-27 니혼 메디피직스 가부시키가이샤 신규 아밀로이드 친화성 화합물
EP2098522B1 (en) * 2006-11-30 2011-10-19 Nihon Medi-Physics Co., Ltd. Compounds having affinity for amyloid
PL2106808T3 (pl) * 2006-12-21 2018-07-31 Nihon Medi-Physics Co., Ltd. Promieniotwórczy znacznik do obrazowania diagnostycznego zawierający kwas 1-amino-3-[18F]fluorocyklobutanokarboksylowy
TWI406674B (zh) 2007-02-13 2013-09-01 日本藥學物理公司 Method for manufacturing diagnostic radiographic diagnostic agents
GB0718386D0 (en) * 2007-09-21 2007-10-31 Ge Healthcare As Improved radiopharmaceutical formulation
TW200918102A (en) * 2007-10-24 2009-05-01 Nihon Mediphysics Co Ltd Novel compound having affinity for amyloid
CN101909658A (zh) * 2007-10-30 2010-12-08 日本医事物理股份有限公司 对淀粉样蛋白具有亲和性的新化合物的应用及制备方法
KR20100089858A (ko) * 2007-10-30 2010-08-12 니혼 메디피직스 가부시키가이샤 신규 아밀로이드 친화성 화합물의 사용 및 제조 방법
WO2009073698A1 (en) * 2007-12-04 2009-06-11 Bracco Imaging S.P.A. Homogenization of a radiopharmaceutical using sonification and/or rotor-stator technology to produce a homogenous suspension, emulsion, mixture or solid suspension of immiscible ingredients
FR2942227B1 (fr) * 2009-02-13 2011-04-15 Guerbet Sa Utilisation de tampons pour la complexation de radionucleides
US9321095B2 (en) 2010-06-30 2016-04-26 General Electric Company Apparatuses and methods for cutting porous substrates
WO2013093099A1 (en) * 2011-12-22 2013-06-27 Piramal Imaging Sa Stabilization of peptidic radiopharmaceuticals using uric acid or derivatives thereof
CN104470547B (zh) 2012-05-24 2018-01-26 未来化学株式会社 利用筒状物合成放射性药物的方法
US20140147381A1 (en) * 2012-11-29 2014-05-29 Gregory David Espenan 89zr compounds, to include somatostatin, apparatus and products comprising such compounds, methods of making same, and methods of using same for radio imaging and/or treatment
KR101652204B1 (ko) * 2014-11-27 2016-08-29 (주)셀트리온 펩타이드가 결합된 안정한 아스코르빈산 유도체, 그의 제조방법 및 그를 포함하는 화장료 조성물
TWI604853B (zh) * 2016-05-03 2017-11-11 行政院原子能委員會核能研究所 放射免疫複合體、診療劑及套組
CN107167540B (zh) * 2017-07-08 2019-07-30 万舒（北京）医药科技有限公司 测定人尿液生物样品中的DTPA-Zn的方法
KR102207372B1 (ko) * 2020-03-31 2021-01-27 재단법인 아산사회복지재단 방사성 의약품의 안정화제 및 이를 포함하는 방사성 의약 조성물

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL42204A (en) * 1972-05-08 1976-09-30 Solco Basel Ag Process and apparatus for the manufacture of injectable radionuclide preparations
US4504462A (en) * 1982-06-10 1985-03-12 Mallinckrodt, Inc. Process for making a lyophilized product for use in skeletal imaging
US4707353A (en) * 1982-12-08 1987-11-17 Mallinckrodt, Inc. Radiographic imaging agents
US5985240A (en) * 1989-08-09 1999-11-16 Rhomed Incorporated Peptide radiopharmaceutical applications
DK0422713T3 (da) * 1989-10-09 1995-04-10 Unilever Plc Spiseligt smøremateriale
DK0600992T3 (da) * 1991-08-29 2000-10-09 Mallinckrodt Medical Inc Anvendelse af gentissyre eller gentisylalkohol til stabilisering af radiomærkede peptider og proteiner
GB9417873D0 (en) 1994-09-06 1994-10-26 Sandoz Ltd Organic compounds
WO1997028181A2 (en) * 1996-02-02 1997-08-07 Rhomed Incorporated Post-labeling stabilization of radiolabeled proteins and peptides
US6066309A (en) * 1996-02-02 2000-05-23 Rhomed Incorporated Post-labeling stabilization of radiolabeled proteins and peptides
US5961955A (en) * 1997-06-03 1999-10-05 Coulter Pharmaceutical, Inc. Radioprotectant for peptides labeled with radioisotope
CA2413538A1 (en) * 2000-07-06 2002-01-17 Bristol-Myers Squibb Pharma Company Stable radiopharmaceutical compositions and methods for preparation thereof

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008056481A1 (en) * 2006-11-09 2008-05-15 Nihon Medi-Physics Co., Ltd. Radioactive diagnostic imaging agent
JPWO2008056481A1 (ja) * 2006-11-09 2010-02-25 日本メジフィジックス株式会社 放射性画像診断剤
JP2012502060A (ja) * 2008-09-05 2012-01-26 モレキュラ インサイト ファーマシューティカルズ インコーポレイテッド 放射性ヨウ素化ベンズアミド誘導体の薬学的組成物およびそれを作製する方法
JP2012524064A (ja) * 2009-04-15 2012-10-11 ランセウス メディカル イメージング， インコーポレイテッド アスコルビン酸による放射性医薬組成物の安定化
US9687571B2 (en) 2009-04-15 2017-06-27 Lantheus Medical Imaging, Inc. Stabilization of radiopharmaceutical compositions using ascorbic acid
JP2016510342A (ja) * 2013-02-15 2016-04-07 トーマス・ジェファーソン・ユニバーシティＴｈｏｍａｓ Ｊｅｆｆｅｒｓｏｎ Ｕｎｉｖｅｒｓｉｔｙ 腫瘍画像化のためのキット

Also Published As

Publication number Publication date
EP1365813A4 (en) 2006-03-22
CA2438204A1 (en) 2002-09-06
WO2002067859A2 (en) 2002-09-06
IL157359A0 (en) 2004-02-19
US6713042B2 (en) 2004-03-30
WO2002067859A3 (en) 2002-11-28
US20020122769A1 (en) 2002-09-05
CN1503680A (zh) 2004-06-09
MXPA03007595A (es) 2003-12-04
HUP0304083A2 (hu) 2004-03-29
BR0207315A (pt) 2004-02-10
EP1365813A2 (en) 2003-12-03
AU2002253999A1 (en) 2002-09-12
CZ20032597A3 (cs) 2004-12-15

Similar Documents

Publication Publication Date Title
US6713042B2 (en) Ascorbic acid analogs for metalloradiopharmaceuticals
Liu The role of coordination chemistry in the development of target-specific radiopharmaceuticals
Sarko et al. Bifunctional chelators in the design and application of radiopharmaceuticals for oncological diseases
Rathmann et al. The radiopharmaceutical chemistry of technetium-99m
Pandya et al. Preliminary therapy evaluation of 225Ac-DOTA-c (RGDyK) demonstrates that Cerenkov radiation derived from 225Ac daughter decay can be detected by optical imaging for in vivo tumor visualization
Carroll et al. Inorganic chemistry in nuclear imaging and radiotherapy: current and future directions
US20020122768A1 (en) Stable radiopharmaceutical compositions and methods for preparation thereof
EP4473980A2 (en) Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of psma-expressing cancers
CA3172811A1 (en) Chelator compositions for radiometals and methods of using same
Blower et al. The radiopharmaceutical chemistry of the radionuclides of gallium and indium
KR20220063214A (ko) Grpr 길항제의 방사성표지 방법 및 이의 키트
CA3171753A1 (en) Stable formulations for radionuclide complexes
Felber et al. Design of PSMA ligands with modifications at the inhibitor part: an approach to reduce the salivary gland uptake of radiolabeled PSMA inhibitors?
US6517814B2 (en) Macrocyclic chelants useful for metallopharmaceuticals
Eberle et al. Receptor-mediated tumor targeting with radiopeptides: Part 1. General principles and methods
Choudhary et al. Chelation in one fell swoop: Optimizing ligands for smaller radiometal ions
Ling et al. The radiopharmaceutical chemistry of the radioisotopes of copper
Liu et al. Radiolabeled integrin αvβ3 antagonists as radiopharmaceuticals for tumor radiotherapy
M Rey Radiometal complexes in molecular imaging and therapy
Boros et al. Coordination chemistry and ligand design in the development of metal based radiopharmaceuticals
Reilly The radiochemistry of monoclonal antibodies and peptides
Reilly The radiopharmaceutical science of monoclonal antibodies and peptides for imaging and targeted in situ radiotherapy of malignancies
Klenner et al. Labeled rhenium complexes: radiofluorination, α-MSH cyclization, and deuterium substitutions
US20020094316A1 (en) Polypodal chelants for metallopharmaceuticals
Vallabhajosula Metal Radionuclides for Molecular Imaging

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050218

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050218

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080610

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20081111